#1 Clinical Trials Search in Europe

Lamivudine

Lamivudine is an antiviral medication that has been extensively studied in clinical trials for the treatment of HIV and chronic hepatitis B infections. This article explores the various ways lamivudine is being investigated, including its use in combination therapies, different dosing regimens, and potential applications in specific patient populations. We’ll examine the efficacy, safety, and long-term outcomes of lamivudine-based treatments as revealed by recent clinical studies.

Table of Contents

What is Lamivudine?

Lamivudine, also known by its brand names Epivir, Zeffix, or Combivir (when combined with other medications), is an antiviral medication used to treat various viral infections[1][2][3]. It belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), which work by interfering with the replication of viruses in the body[1].

Uses of Lamivudine

Lamivudine is primarily used to treat two main conditions:

  1. HIV Infection: Lamivudine is an essential component of many antiretroviral therapy (ART) regimens used to treat Human Immunodeficiency Virus (HIV) infection[4][5]. It is often combined with other antiretroviral drugs to create effective treatment plans for people living with HIV.
  2. Chronic Hepatitis B: Lamivudine is also used to treat chronic hepatitis B virus (HBV) infection in adults[6][2]. It can help reduce the amount of hepatitis B virus in the body and improve liver function.

How Lamivudine Works

Lamivudine works by interfering with the replication process of viruses like HIV and HBV. Here’s a simplified explanation of how it functions:

  • When viruses like HIV or HBV infect cells, they use an enzyme called reverse transcriptase to replicate their genetic material.
  • Lamivudine mimics one of the building blocks (nucleosides) that the virus needs to create new copies of itself.
  • When the virus tries to use lamivudine instead of the real nucleoside, it disrupts the replication process, preventing the virus from making new copies efficiently[1].

By reducing viral replication, lamivudine helps lower the amount of virus in the body, which can slow down the progression of the disease and improve the patient’s overall health.

Dosage and Administration

Lamivudine is typically taken orally in tablet form. The dosage can vary depending on the condition being treated and other factors. Here are some common dosing regimens:

  • For HIV treatment: 300 mg once daily or 150 mg twice daily, often as part of a combination therapy[1].
  • For chronic hepatitis B: 100 mg once daily[2].

It’s important to note that dosages may be adjusted based on individual patient factors, such as kidney function or age. Always follow your healthcare provider’s instructions regarding dosage and administration.

Effectiveness

Lamivudine has shown effectiveness in treating both HIV and chronic hepatitis B:

  • In HIV treatment, lamivudine is often used as part of combination antiretroviral therapy. It helps suppress viral replication, leading to reduced HIV RNA levels in the blood (viral load) and improved CD4+ T cell counts, which are important markers of immune system health[4][5].
  • For chronic hepatitis B, lamivudine can help normalize liver enzyme levels, reduce HBV DNA levels, and in some cases, lead to HBeAg seroconversion (a sign of improved immune control over the virus)[6].

However, it’s important to note that the effectiveness of lamivudine can be limited by the development of drug resistance, especially when used as monotherapy (single-drug treatment) for extended periods[7].

Side Effects and Safety

Like all medications, lamivudine can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Fatigue
  • Diarrhea
  • Abdominal pain

More serious side effects, though less common, can include:

  • Lactic acidosis (a buildup of lactic acid in the body)
  • Liver problems
  • Changes in body fat distribution

It’s important to discuss any side effects with your healthcare provider. Regular monitoring of liver function, kidney function, and blood tests may be necessary while taking lamivudine[1].

Ongoing Research

Research on lamivudine continues to explore its potential uses and optimize its effectiveness:

  • Studies are investigating the use of lamivudine in combination with other antiretroviral drugs to improve treatment outcomes and reduce side effects in HIV patients[5].
  • Research is ongoing to determine the optimal duration of lamivudine therapy for chronic hepatitis B patients and to develop strategies to prevent or manage drug resistance[2].
  • Interestingly, some research is exploring the potential use of lamivudine in treating certain types of cancer, such as p53 mutant metastatic colorectal cancer[3]. However, this is still in the experimental stage and not an approved use of the drug.

As research progresses, our understanding of lamivudine’s benefits and optimal use continues to evolve. Always consult with your healthcare provider for the most up-to-date information about your treatment options.

Aspect Details
HIV Treatment – Studied in combination with other antiretrovirals (e.g., dolutegravir) – Investigated as part of two-drug regimens – Compared to three-drug regimens for efficacy and safety – Assessed for patient satisfaction and quality of life
Hepatitis B Treatment – Evaluated for long-term efficacy in chronic hepatitis B – Explored as extended therapy after initial treatment – Combined with other drugs (e.g., oxymatrine) to improve outcomes – Studied for reduction of drug resistance
Dosing Studies – Compared pharmacokinetics of 300mg vs 150mg daily doses – Investigated potential for lower effective doses – Aimed at reducing side effects while maintaining efficacy
Other Applications – Explored as potential treatment for p53 mutant metastatic colorectal cancer
Key Outcomes Measured – Viral load suppression – CD4 count changes – Adverse events and tolerability – Drug resistance development – Quality of life improvements
Patient Populations – HIV-positive individuals – Chronic hepatitis B patients – Older adults (60 years and above) – Treatment-naïve and treatment-experienced patients

FAQ

  • What is lamivudine and what is it used for? Lamivudine is an antiviral medication used to treat HIV and chronic hepatitis B infections. It works by preventing the viruses from multiplying in the body.
  • How is lamivudine being studied in HIV treatment? Lamivudine is being studied in combination with other antiretroviral drugs, such as dolutegravir, as part of two-drug regimens for HIV treatment. Researchers are investigating its efficacy, safety, and patient satisfaction compared to three-drug regimens.
  • What are researchers exploring about lamivudine in hepatitis B treatment? Studies are examining the long-term efficacy of lamivudine in chronic hepatitis B patients, its potential for extending therapy after initial treatment, and its combination with other drugs like oxymatrine to improve outcomes and reduce drug resistance.
  • Are there any studies looking at different doses of lamivudine? Yes, some studies are comparing the pharmacokinetics and efficacy of different lamivudine doses, such as 300mg versus 150mg daily, to determine if lower doses could be effective while potentially reducing side effects.
  • Is lamivudine being studied for any other conditions? Interestingly, lamivudine is also being investigated as a potential treatment for p53 mutant metastatic colorectal cancer, exploring its ability to prevent cancer cell growth and spread.

Ongoing Clinical Trials on Lamivudine

  • A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

    Recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study Comparing Doravirine/Lamivudine and Dolutegravir/Lamivudine for HIV Patients with Controlled Viral Load on Three-Drug Regimens

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Reducing HIV Latent Reservoirs Using High Doses of Lamivudine, Maraviroc, and Dolutegravir Sodium for Patients with HIV Infection

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effects of Abacavir and Lamivudine in Patients with Systemic Lupus Erythematosus with Low Disease Activity

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Doravirine, Tenofovir Disoproxil, and Lamivudine in HIV Patients with M184V/I Mutation and Controlled Viral Load

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on HIV Treatment Interruption in Children with Perinatal HIV Using Lamivudine and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Early Switching to Dolutegravir and Lamivudine for Adults with HIV-1 on Three-Drug Regimen with Virological Suppression

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Italy

Glossary

  • Lamivudine: An antiviral medication used to treat HIV and chronic hepatitis B infections by preventing virus replication.
  • Antiretroviral therapy (ART): Treatment for HIV that uses a combination of medications to suppress the virus and slow the progression of the disease.
  • Viral load: The amount of virus in a person's blood, often measured to determine the effectiveness of treatment.
  • CD4 count: A measure of the number of CD4 T cells in the blood, which helps assess the strength of the immune system in HIV patients.
  • Virologic suppression: When antiretroviral therapy reduces a person's viral load to an undetectable level, typically less than 50 copies/mL.
  • HBeAg seroconversion: The loss of hepatitis B e antigen (HBeAg) and development of antibodies against it, often indicating improved control of hepatitis B infection.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Drug resistance: When a virus develops mutations that make it less susceptible to the effects of antiviral medications.
  • Adverse events: Undesirable side effects or medical occurrences associated with the use of a medication during a clinical study.
  • Quality of life (QoL): A measure of an individual's overall well-being and satisfaction with life, often assessed in clinical trials to determine the impact of treatment on patients' daily lives.

References

  1. https://clinicaltrials.gov/study/NCT00985647
  2. https://clinicaltrials.gov/study/NCT02337127
  3. https://clinicaltrials.gov/study/NCT03144804
  4. https://clinicaltrials.gov/study/NCT02342769
  5. https://clinicaltrials.gov/study/NCT06444620
  6. https://clinicaltrials.gov/study/NCT00354653
  7. https://clinicaltrials.gov/study/NCT01546116